scispace - formally typeset
H

Hanne Meijers-Heijboer

Researcher at VU University Amsterdam

Publications -  38
Citations -  6331

Hanne Meijers-Heijboer is an academic researcher from VU University Amsterdam. The author has contributed to research in topics: Breast cancer & Population. The author has an hindex of 24, co-authored 38 publications receiving 5569 citations. Previous affiliations of Hanne Meijers-Heijboer include VU University Medical Center & Agency for Science, Technology and Research.

Papers
More filters
Journal ArticleDOI

Large-scale genotyping identifies 41 new loci associated with breast cancer risk

Kyriaki Michailidou, +220 more
- 01 Apr 2013 - 
TL;DR: A meta-analysis of 9 genome-wide association studies, including 10,052 breast cancer cases and 12,575 controls of European ancestry, and identified 29,807 SNPs for further genotyping suggests that more than 1,000 additional loci are involved in breast cancer susceptibility.
Journal ArticleDOI

MicroRNA related polymorphisms and breast cancer risk

Sofia Khan, +161 more
- 12 Nov 2014 - 
TL;DR: Five miRNA binding site SNPs associated significantly with breast cancer risk are located in the 3′ UTR of CASP8, HDDC3, DROSHA, MUSTN1, and MYCL1, respectively, which belongs to miRNA machinery genes and has a central role in initial miRNA processing.
Journal ArticleDOI

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

Stig E. Bojesen, +455 more
- 01 Apr 2013 - 
TL;DR: Using the Illumina custom genotyping array iCOGs, SNPs at the TERT locus in breast, ovarian and BRCA1 mutation carrier cancer cases and controls and leukocyte telomere measurements are analyzed to find associations cluster into three independent peaks.
Journal ArticleDOI

Genome-wide association studies identify four ER negative-specific breast cancer risk loci

Montserrat Garcia-Closas, +287 more
- 01 Apr 2013 - 
TL;DR: SNPs at four loci were associated with ER-negative but not ER-positive breast cancer (P > 0.05), providing further evidence for distinct etiological pathways associated with invasive ER- positive and ER- negative breast cancers.